CONCORD, Calif. & CHARLOTTE, N.C.--(BUSINESS WIRE)--
Cerus Corporation (NASDAQ:CERS) announced today that the Community Blood
Center of the Carolinas (CBCC) has signed a three-year purchase
agreement for the INTERCEPT Blood System for platelets and plasma. CBCC
provides over 12,000 platelet and 22,000 plasma units annually to 27
regional hospitals.
“Our goal is to provide blood components of the highest possible level
of quality and safety for the hospitals and patients we serve," said
Martin Grable, CBCC's president and chief executive officer.
“INTERCEPT-treated platelets and plasma enable us to offer an even safer
choice of blood components in the Carolinas.”
“We are proud to work with CBCC to bring pathogen-reduced platelets and
plasma to the Carolinas. We believe everyone should have access to
pathogen-reduced platelets and plasma and CBCC’s goal of providing blood
components with the highest quality and safety standards is consistent
with Cerus' own mission,” commented William 'Obi' Greenman, Cerus’
president and chief executive officer.
ABOUT COMMUNITY BLOOD CENTER OF THE CAROLINAS
The Community Blood Center of the Carolinas (CBCC) is a non-profit
community-based blood center and the primary blood supplier to 27
regional hospitals, serving 19 North Carolina and three South Carolina
counties. It focuses exclusively on gathering red blood cells, platelets
and plasma from volunteer donors to save local lives in the Carolinas.
CBCC is a member of America’s Blood Centers, North America’s largest
network of community-based, independent blood centers, providing more
than 50% of the nation’s blood supply. For more information, visit http://www.cbcc.us.
ABOUT CERUS
Cerus Corporation is a biomedical products company focused in the field
of blood safety. The INTERCEPT Blood System is designed to reduce the
risk of transfusion-transmitted infections by inactivating a broad range
of pathogens such as viruses, bacteria and parasites that may be present
in donated blood. The nucleic acid targeting mechanism of action of the
INTERCEPT treatment is designed to inactivate established transfusion
threats, such as Hepatitis B and C, HIV, West Nile Virus and bacteria,
as well as emerging pathogens such as chikungunya, malaria and dengue.
Cerus currently markets and sells the INTERCEPT Blood System for both
platelets and plasma in the United States, Europe, the Commonwealth of
Independent States, the Middle East and selected countries in other
regions around the world. The INTERCEPT red blood cell system is in
clinical development. See http://www.cerus.com
for information about Cerus.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151006005610/en/
Source: Cerus Corporation